QLGN News and Press, Qualigen Therapeutics Inc. From 03/08/21

CARLSBAD, Calif., March 08, 2021 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN), a biotechnology company focused on developing novel therapeutics for the treatment of cancer and viral diseases, announced today that Michael Poirier, President, Chief Executive Officer and Chai...

CARLSBAD, Calif., March 01, 2021 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) , a biotechnology company focused on developing novel therapeutics for the treatment of cancer and viral diseases, announced today it has entered into a Material Evaluation and Option Agreeme...

4 Penny Stocks To Watch With Increased Volume This Month Penny stocks were in direct focus on Wednesday. Partially thanks to surging prices in names like Express and GameStop, traders were seeking volatility. It was also a topic of conversation on countless financial outlets (obviou...

Qualigen Therapeutics Announces Completion of Milestone Related to the License and Technology Transfer of its FastPack® Diagnostics Products in China PR Newswire CARLSBAD, Calif. , Jan. 26, 2021 /PRNewswire/ -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN),...

La Jolla Pharmaceutical (LJPC) +62% on exclusive licensing agreement with PAIONVOXX International (VOXX) +56% after posting strong sales growth.T2 Biosystems (TTOO) +33% after the company says its T2SARS-CoV-2 Panel is capable of detecting multiple variants of the COVID-19 viru...

Qualigen Therapeutics to Present at the H.C. Wainwright BioConnect 2021 Conference PR Newswire CARLSBAD, Calif. , Jan. 5, 2021 /PRNewswire/ -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a biotechnology company focused on developing novel therapeutics fo...

Qualigen Therapeutics Issues CEO Letter to Stockholders with 2021 Outlook PR Newswire CARLSBAD, Calif. , Dec. 22, 2020 /PRNewswire/ -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN) , a biotechnology company focused on developing novel therapeutics for the t...

Qualigen Therapeutics, Inc. Announces Closing of $12 Million Registered Direct Offering PR Newswire CARLSBAD, Calif. , Dec. 18, 2020 /PRNewswire/ -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN) today announced the closing of its previously announced r...

Qualigen Therapeutics ([[QLGN]] -8.4%) has entered into a definitive agreement with a single institutional investor for $12M direct offering, expected to close on Dec. 18, 2020.It includes sale and purchase of: (i) 2,370,786 Qualigen's common shares, (ii) 1,000,000 pre-funded w...

Qualigen Therapeutics, Inc. Announces $12 Million Registered Direct Offering CARLSBAD, Calif. , Dec. 16, 2020 /PRNewswire/ -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) ("Qualigen" or the "Company"), today announced it has entered into a definitive agreement wi...